Purchase this article with an account.
Shan Fan, Lisa Reid, Toni L. Goeser, Ganesh Prasanna, Carol B Toris; Effects of a proprietary de-novo IOP lowering compound (ID-65-CW69) on aqueous humor dynamics in monkeys. Invest. Ophthalmol. Vis. Sci. 2021;62(8):546.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
The purpose of this study was to identify the mechanism by which a novel selective soluble guanylate cyclase activator (ID-65-CW69) lowers intraocular pressure (IOP) and alters aqueous humor dynamics in monkeys with unilateral laser induced glaucoma.
Fifteen female cynomolgus monkeys with unilateral laser-induced glaucoma were dosed with one 30 µl drop of ID-65-CW69 or its vehicle to the cornea of both eyes at 6:00 PM the day before the measurement day in a masked crossover fashion. Intraocular pressures (mmHg) were measured by pneumatonometry at 6:00 PM (IOP1), just before dosing; and again at10:00AM (IOP2) and noon (IOP3) the following day. Other measurements were aqueous flow (Fa, μl/min) by fluorophotometry, outflow facility (C, μl/min/mmHg) by fluorophotometry (C) and uveoscleral outflow (Fu, μl/min) by mathematical calculation.
The hypertensive eyes showed a significant decrease in IOP to the level of the normotensive eyes. Results in the hypertensive eyes are summarized in the Table. Values are Means±SD. Drug treatments and corresponding vehicle treatments were compared by two-tailed paired t-tests (p). No significant changes were found in the normotensive eyes.
ID-65-CW69 reduced IOP in hypertensive eyes by increasing uveoscleral outflow by over two-fold. Outflow facility increased but this did not reach significance. The drug did not significantly lower IOP in the normotensive eyes.
This is a 2021 ARVO Annual Meeting abstract.
This PDF is available to Subscribers Only